Daily Brief Health Care: Scribe Therapeutics, Eli Lilly & Co, AstraZeneca, Starton Holdings, Encore Medical, Lexaria Bioscience and more

• Scribe Therapeutics is a clinical-stage biotech company engineering in vivo CRISPR technologies for disease prevention and durable therapeutic intervention, funding development via IPO.
• Scribe initiated a first-in-human trial for STX-1150 (LDL-C reduction), with initial data expected in H1 2027, and received $25.7 million grant funding.
• The company reported a net loss of $(17,347) for Q1 2026, an accumulated deficit of $(175,054), and substantial doubt about its going concern ability.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Eli Lilly and Company has intensified its push beyond obesity and diabetes by agreeing to acquire AtaiBeckley for as much as $3.8 billion, including $2.8 billion upfront and up to $1 billion tied to milestones.
• The proposed transaction would give Lilly control of BPL-003, a late-stage psychedelic nasal spray being developed for treatment-resistant depression, with pivotal data expected in early 2029 and estimated peak annual sales potential of $1 billion to $2 billion.
• The move follows a strong first quarter in which Lilly’s revenue rose 56%, while its immunology, oncology and neuroscience products collectively grew 160%.

• AstraZeneca has agreed to acquire exclusive global development and commercialization rights to Zegfrovy, a lung cancer treatment developed by China’s Dizal Pharmaceutical, in a transaction worth up to $1.5 billion.
• The company will pay $600 million upfront, with as much as $900 million in additional payments linked to specified milestones, while Dizal will also receive tiered royalties on future sales.
• Zegfrovy is already approved in the United States and China for adults with locally advanced or metastatic non-small cell lung cancer, giving AstraZeneca an asset that has moved beyond the earliest and riskiest stages of drug development.

• Starton Holdings, a clinical-stage biotechnology company, uses its proprietary continuous delivery platform to improve cancer therapies, funding STAR-LLD development via an IPO.
• The company holds 8 issued patents and has STAR-LLD-SC in Phase 2a for RRMM. STAR-LLD-OCR entered human study in Q1/2026.
• The company reported a $15.4 million net loss for 2026 and an $89.2 million accumulated deficit, raising substantial doubt about its “going concern” ability.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Encore Medical is a structural heart device company focused on transcatheter closure of cardiac defects, developing and marketing septal occlusion products. This offering finances U.S. clinical trials for stroke and.
• Encore Medical has over 35,000 successful global implants and CE Mark approval. FDA IDE approval for a U.S. stroke trial targets a potential $1.5 billion market.
• Encore Medical reported $2.58 million revenue in 2025, but incurred a $0.92 million net loss. An auditor opinion raises substantial doubt about its ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology employing oral and topical delivery.
• It combines lipophilic APIs with specific fatty acid and carrier compounds, followed by dehydration.
• DHT offers several attractive features: 1) substantial improvement in bioabsorption in terms of time to measurable plasma levels & AUC, 2) brain permeation, 3) taste masking & 4) side effect reduction.